Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

851 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study.
Kübler H, Scheel B, Gnad-Vogt U, Miller K, Schultze-Seemann W, Vom Dorp F, Parmiani G, Hampel C, Wedel S, Trojan L, Jocham D, Maurer T, Rippin G, Fotin-Mleczek M, von der Mülbe F, Probst J, Hoerr I, Kallen KJ, Lander T, Stenzl A. Kübler H, et al. Among authors: stenzl a. J Immunother Cancer. 2015 Jun 16;3:26. doi: 10.1186/s40425-015-0068-y. eCollection 2015. J Immunother Cancer. 2015. PMID: 26082837 Free PMC article.
Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients.
Rittig SM, Haentschel M, Weimer KJ, Heine A, Muller MR, Brugger W, Horger MS, Maksimovic O, Stenzl A, Hoerr I, Rammensee HG, Holderried TA, Kanz L, Pascolo S, Brossart P. Rittig SM, et al. Among authors: stenzl a. Mol Ther. 2011 May;19(5):990-9. doi: 10.1038/mt.2010.289. Epub 2010 Dec 28. Mol Ther. 2011. PMID: 21189474 Free PMC article. Clinical Trial.
A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium.
Miller K, Morant R, Stenzl A, Zuna I, Wirth M. Miller K, et al. Among authors: stenzl a. Urol Int. 2016;96(1):5-13. doi: 10.1159/000381589. Epub 2015 Jun 6. Urol Int. 2016. PMID: 26068576 Clinical Trial.
Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy.
Rittig SM, Haentschel M, Weimer KJ, Heine A, Müller MR, Brugger W, Horger MS, Maksimovic O, Stenzl A, Hoerr I, Rammensee HG, Holderried TA, Kanz L, Pascolo S, Brossart P. Rittig SM, et al. Among authors: stenzl a. Oncoimmunology. 2015 Oct 29;5(5):e1108511. doi: 10.1080/2162402X.2015.1108511. eCollection 2016 May. Oncoimmunology. 2015. PMID: 27467913 Free PMC article.
851 results